Patient Demographics and Baseline Disease Characteristics in MARIPOSA-2

Opinion
Video

In this segment the panelist reviews the baseline patient and disease characteristics across the three treatment arms in MARIPOSA-2.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Related Content